Michael Poch, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Ferring Pharmaceuticals Inc. accounts for 61.8% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $6,506, more than ten times the $72 reported in 2019.
Across 17 payments — averaging $395.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$4K
- Janssen Scientific Affairs, LLC$2K
- Johnson & Johnson$853
- BD$80
- Rochester Medical Corporation$37
- Baxter Healthcare$34
Across 1 payment — averaging $133,235 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clinigen, Inc.$133K
What the payments were for
- Consulting fees$2,18032%
- Speaking & faculty fees$3,80057%
- Food & beverage$74511%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 5 | $4,158 |
| Janssen Scientific Affairs, LLC | 4 | $1,563 |
| Johnson & Johnson | 2 | $853 |
| BD | 4 | $80 |
| Rochester Medical Corporation | 1 | $37 |
| Baxter Healthcare | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$3,800
How this compares
$6,725 in reported general payments places this provider in the 65th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 19 | $247 |
| Oxybutynin Chloride | 15 | $78 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $24 |
Paid to pharmacies, not to this prescriber.
Other urology in Tampa
- Rafael CarrionTampa$240K
- Raviender BukkapatnamTampa$115K
- Trushar PatelTampa$88K
- Paul PeritoCoral Gables$3.6M
- Scott SellingerTallahassee$2.3M
- Mark Anthony GonzalgoMiami$1M
- Edward GheilerHialeah$655K
- Rolando RiveraNaples$437K
- Matthew ErcolaniVenice$416K
- Olubayo TojuolaOrlando$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.